EAD1 is a potent and selective autophagy inhibitor with antiproliferative activity in lung and pancreatic cancer cells. EAD1 had an IC50 of 5.8 μM in the BxPC3 cells and was approximately 8-fold more potent than CQ and HCQ. EAD1 inhibited autophagy, as judged by the cellular accumulation of the autophagy-related autophagosome proteins LC3-II and p62 and induced apoptosis. The increases in LC3-II levels by the analogues were highly correlated with their growth inhibitory IC50s, suggesting that autophagy blockade is closely linked to inhibition of cell proliferation. EAD1 is a viable lead compound for evaluation of the antitumor activity of autophagy inhibitors in vivo. References: Nordstrom LU, Sironi J, Aranda E, Maisonet J, Perez-Soler R, Wu P, Schwartz EL. Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells. ACS Med Chem Lett. 2015 Jan 8;6(2):134-9. doi: 10.1021/ml500348p. eCollection 2015 Feb 12. PubMed PMID: 25699157; PubMed Central PMCID: PMC4329578.

纯度：≥98%

CAS：1644388-26-0